Skip to main content

Table 4 Associations and impact between the risk intraepithelial lesion/malignancy and the vaccine-targeted high-risk HPV genotypes

From: Prevalence of high-risk HPV genotypes, categorised by their quadrivalent and nine-valent HPV vaccination coverage, and the genotype association with high-grade lesions

   No lesion Intraepithelial lesion or malignancya          
   n = 509 n = 81 ORc 95%CI   ORa 95%CI   AFe-a 95%CI  
Regarding HPV genotype
 No high-riskb   154 6 1   1     
 At least 1 high-risk   355 75 5.42 2.31 12.72 6.01 2.53 14.29 0.83 0.60 0.93
According to the vaccine-targeted high-risk HPV genotypes
 No high-riskb   154 6 1   1     
 Quadrivalent HPV non-vaccine-targeted high-risk HPV genotypesc   208 20 2.47 0.97 6.29 2.71 1.05 7.01 0.63 0.04 0.86
  Quadrivalent HPV and nine-valent HPV non-vaccine-targeted high-risk HPV genotypesd 101 6 1.53 0.48 4.86 1.76 0.54 5.70 0.43
  Additional five high-risk HPV genotypes present in the nine-valent HPV vaccinee 107 14 3.36 1.25 9.02 3.51 1.29 9.56 0.72 0.22 0.90
 Vaccine-targeted high-risk HPV genotypes (16 or 18)   145 52 9.21 3.84 22.08 10.40 4.25 25.40 0.90 0.76 0.96
 Vaccine-targeted high-risk HPV genotypes (16 and 18)   2 3 38.50 5.39 275.06 63.58 8.62 468.70 0.98 0.88 1.00
     <  0.001   <  0.001     
  1. aIntraepithelial lesion or malignancy: high-grade squamous intraepithelial lesion or worse
  2. Odds ratio and 95% confidence intervals. ORc denotes “crude OR”; ORa denotes “adjusted OR” OR adding to the basic model: age and immigrant status
  3. AFe-a: Attributable fraction among the exposed, adjusted for age and immigrant status
  4. bNo high-risk. Classification of human papillomavirus (HPV) types according to the World Health Organization International Agency for Research on Cancer (IARC) Monographs Working Group assessment of the carcinogenicity of different HPV types [25,26,27]
  5. cAt least 1 of the quadrivalent HPV non-vaccine-targeted high-risk HPV genotypes (31 or 33 or 35 or 39 or 45 or 51 or 52 or 56 or 58 or 59 or 68)
  6. dAt least 1 of the quadrivalent HPV and nine-valent HPV non-vaccine-targeted high-risk HPV genotypes (35 or 39 or 51 or 56 or 59 or 68)
  7. eAt least 1 of the additional five high-risk HPV genotypes present in the nine-valent HPV vaccine (31 or 33 or 45 or 52 or 58)